Related Experiment Video
Updated: May 10, 2026
12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
IL-17 targeted therapies for psoriasis
Andrea Chiricozzi1, James G Krueger
1The Rockefeller University, Laboratory for Investigative Dermatology , 1230 York Avenue, New York City, NY 10065, USA. chiricozziandrea@gmail.com
Expert Opinion on Investigational Drugs
|June 5, 2013
Summary
New biologic therapies targeting interleukin-17A (IL-17A) show significant promise for treating psoriasis. Blocking IL-17A effectively reduces disease severity, indicating its crucial role in this chronic inflammatory skin condition.
Area of Science:
- Immunodermatology
- Inflammatory skin diseases
- Cytokine signaling
Background:
- Psoriasis is a chronic inflammatory skin disease with incompletely understood pathogenesis.
- Immune responses involving cytokines like IL-17A are implicated in psoriasis development.
- Genetic and environmental factors contribute to the immune dysregulation seen in psoriasis.
Purpose of the Study:
- To review the role of IL-17A in psoriasis pathogenesis.
- To discuss the development and efficacy of IL-17-targeted therapies.
- To evaluate the potential impact of IL-17 blockade on psoriasis comorbidities.
Main Methods:
- Review of emerging evidence on IL-17A's role in psoriasis.
- Analysis of Phase II and III clinical trial data for IL-17 inhibitors (secukinumab, ixekizumab, brodalumab).
- Assessment of therapeutic efficacy and safety profiles of anti-IL-17 agents.
Main Results:
- IL-17A is confirmed as a central mediator in psoriasis pathogenesis.
- Phase II trials demonstrated marked improvement in psoriasis severity with IL-17 blockade.
- Agents targeting IL-17 or its receptor show significant efficacy in clinical studies.
Conclusions:
- Anti-IL-17 agents are poised to become key therapeutics for psoriasis.
- These therapies may positively influence psoriasis comorbidities such as cardiovascular disease and arthritis.
- Targeting the IL-17 pathway offers a promising therapeutic strategy for managing psoriasis and its associated conditions.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.